| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 28 | 2025 | 604 | 4.170 |
Why?
|
| Insulin-Secreting Cells | 13 | 2025 | 177 | 2.580 |
Why?
|
| Islets of Langerhans | 11 | 2024 | 271 | 2.350 |
Why?
|
| CD4-Positive T-Lymphocytes | 17 | 2024 | 621 | 1.520 |
Why?
|
| T-Lymphocytes | 11 | 2025 | 970 | 1.320 |
Why?
|
| Autoimmunity | 6 | 2021 | 222 | 0.760 |
Why?
|
| T-Lymphocyte Subsets | 7 | 2021 | 237 | 0.730 |
Why?
|
| Autoantigens | 5 | 2018 | 125 | 0.720 |
Why?
|
| Pancreas | 5 | 2023 | 146 | 0.710 |
Why?
|
| Epitopes, T-Lymphocyte | 5 | 2023 | 178 | 0.600 |
Why?
|
| Lymph Nodes | 3 | 2017 | 215 | 0.590 |
Why?
|
| Insulin | 8 | 2021 | 692 | 0.580 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 10 | 0.560 |
Why?
|
| HLA-DQ Antigens | 1 | 2016 | 14 | 0.540 |
Why?
|
| HLA-A2 Antigen | 1 | 2016 | 65 | 0.530 |
Why?
|
| Antigen Presentation | 6 | 2025 | 228 | 0.410 |
Why?
|
| Killer Cells, Natural | 4 | 2006 | 215 | 0.380 |
Why?
|
| Histocompatibility Antigens Class II | 7 | 2019 | 179 | 0.350 |
Why?
|
| Lymphocyte Activation | 8 | 2018 | 742 | 0.320 |
Why?
|
| Peptides | 8 | 2025 | 549 | 0.320 |
Why?
|
| Humans | 45 | 2025 | 60081 | 0.320 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2018 | 280 | 0.290 |
Why?
|
| Interleukin-4 | 4 | 2006 | 141 | 0.280 |
Why?
|
| Antigens | 2 | 2018 | 146 | 0.280 |
Why?
|
| B-Lymphocytes | 5 | 2017 | 552 | 0.280 |
Why?
|
| Antigens, CD1 | 7 | 2008 | 42 | 0.270 |
Why?
|
| Amino Acid Sequence | 7 | 2017 | 1572 | 0.260 |
Why?
|
| Th1 Cells | 4 | 2009 | 174 | 0.250 |
Why?
|
| HLA-B Antigens | 1 | 2025 | 14 | 0.240 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2000 | 112 | 0.240 |
Why?
|
| Interferon-alpha | 1 | 2025 | 99 | 0.230 |
Why?
|
| Coxsackievirus Infections | 1 | 2024 | 12 | 0.230 |
Why?
|
| Immunotherapy | 2 | 2025 | 235 | 0.210 |
Why?
|
| Cytokines | 5 | 2009 | 911 | 0.210 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2025 | 651 | 0.210 |
Why?
|
| Epitopes | 3 | 2024 | 294 | 0.210 |
Why?
|
| Animals | 16 | 2023 | 19739 | 0.210 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 128 | 0.210 |
Why?
|
| Cell Line, Transformed | 3 | 2018 | 96 | 0.190 |
Why?
|
| Clone Cells | 7 | 2016 | 106 | 0.190 |
Why?
|
| Antigens, Neoplasm | 1 | 2022 | 136 | 0.180 |
Why?
|
| Protein Precursors | 1 | 2021 | 73 | 0.180 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 157 | 0.180 |
Why?
|
| HLA-DR Antigens | 3 | 2011 | 27 | 0.180 |
Why?
|
| Mice | 9 | 2023 | 10317 | 0.170 |
Why?
|
| C-Peptide | 3 | 2016 | 23 | 0.170 |
Why?
|
| Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 6 | 0.170 |
Why?
|
| Complementarity Determining Regions | 1 | 1999 | 37 | 0.160 |
Why?
|
| Tissue Array Analysis | 2 | 2010 | 31 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2025 | 560 | 0.150 |
Why?
|
| Hybridomas | 1 | 2018 | 65 | 0.150 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2018 | 256 | 0.150 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2018 | 38 | 0.150 |
Why?
|
| Antibodies | 3 | 2024 | 176 | 0.150 |
Why?
|
| Proinsulin | 1 | 2017 | 3 | 0.150 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2018 | 75 | 0.140 |
Why?
|
| Diabetes Complications | 1 | 2018 | 102 | 0.140 |
Why?
|
| Adolescent | 6 | 2017 | 5944 | 0.140 |
Why?
|
| Immune Tolerance | 3 | 2016 | 171 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2018 | 108 | 0.140 |
Why?
|
| Adult | 11 | 2025 | 15972 | 0.140 |
Why?
|
| Germinal Center | 1 | 2017 | 38 | 0.140 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2016 | 14 | 0.130 |
Why?
|
| Brain | 1 | 2025 | 1485 | 0.130 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2016 | 201 | 0.130 |
Why?
|
| Antigens, CD1d | 4 | 2005 | 27 | 0.130 |
Why?
|
| Somatostatin-Secreting Cells | 1 | 2015 | 8 | 0.120 |
Why?
|
| Glucagon-Secreting Cells | 1 | 2015 | 26 | 0.120 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2016 | 194 | 0.120 |
Why?
|
| Fetus | 1 | 2015 | 97 | 0.120 |
Why?
|
| Molecular Sequence Data | 6 | 2016 | 1965 | 0.120 |
Why?
|
| Lipids | 2 | 2008 | 306 | 0.120 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 2 | 2008 | 24 | 0.120 |
Why?
|
| Cells, Cultured | 7 | 2019 | 2095 | 0.120 |
Why?
|
| Male | 13 | 2025 | 27951 | 0.110 |
Why?
|
| Dendritic Cells | 4 | 2017 | 508 | 0.110 |
Why?
|
| Immunophenotyping | 3 | 2022 | 185 | 0.110 |
Why?
|
| Young Adult | 4 | 2017 | 4398 | 0.110 |
Why?
|
| Risk Factors | 1 | 2023 | 5090 | 0.110 |
Why?
|
| Female | 13 | 2025 | 31226 | 0.110 |
Why?
|
| Child | 4 | 2017 | 4313 | 0.110 |
Why?
|
| Alternative Splicing | 2 | 2025 | 121 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2018 | 538 | 0.100 |
Why?
|
| Interleukin-17 | 2 | 2010 | 82 | 0.100 |
Why?
|
| RNA | 1 | 2015 | 404 | 0.090 |
Why?
|
| Myelin-Associated Glycoprotein | 1 | 2011 | 12 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 630 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2008 | 240 | 0.090 |
Why?
|
| HLA-DRB1 Chains | 2 | 2011 | 12 | 0.090 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2000 | 32 | 0.090 |
Why?
|
| Peptide Fragments | 1 | 2011 | 353 | 0.080 |
Why?
|
| Cysteine | 1 | 2010 | 109 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2018 | 1064 | 0.080 |
Why?
|
| Interferon-gamma | 6 | 2010 | 550 | 0.080 |
Why?
|
| CD4 Antigens | 2 | 2006 | 156 | 0.080 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 109 | 0.080 |
Why?
|
| Immunoassay | 1 | 2008 | 52 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2011 | 209 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 170 | 0.080 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2008 | 35 | 0.080 |
Why?
|
| Genes, myc | 2 | 2001 | 19 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2010 | 198 | 0.070 |
Why?
|
| Antigen-Presenting Cells | 2 | 2005 | 176 | 0.070 |
Why?
|
| Aspartic Acid Endopeptidases | 1 | 2008 | 29 | 0.070 |
Why?
|
| Cysteine Endopeptidases | 1 | 2008 | 91 | 0.070 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 130 | 0.070 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2008 | 174 | 0.070 |
Why?
|
| Monocytes | 1 | 2009 | 344 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 280 | 0.070 |
Why?
|
| Lysosomes | 1 | 2008 | 159 | 0.070 |
Why?
|
| Graft Rejection | 1 | 2008 | 264 | 0.070 |
Why?
|
| Cell Communication | 2 | 2021 | 127 | 0.070 |
Why?
|
| Biomarkers | 2 | 2022 | 1214 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2008 | 156 | 0.070 |
Why?
|
| Cell Differentiation | 2 | 2009 | 1298 | 0.060 |
Why?
|
| Tissue Donors | 2 | 2021 | 134 | 0.060 |
Why?
|
| Autoantibodies | 3 | 2017 | 175 | 0.060 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2005 | 25 | 0.060 |
Why?
|
| Apolipoproteins E | 1 | 2005 | 98 | 0.060 |
Why?
|
| Tuberculosis | 1 | 2008 | 268 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2017 | 1839 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2016 | 516 | 0.060 |
Why?
|
| Congresses as Topic | 1 | 2025 | 74 | 0.060 |
Why?
|
| Substrate Specificity | 1 | 2005 | 325 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2008 | 389 | 0.060 |
Why?
|
| Chromatography, Liquid | 1 | 2024 | 120 | 0.060 |
Why?
|
| Alleles | 1 | 2005 | 417 | 0.050 |
Why?
|
| Membrane Proteins | 1 | 2009 | 847 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2022 | 638 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 2 | 1994 | 59 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2024 | 135 | 0.050 |
Why?
|
| Salmonella Infections | 1 | 2003 | 38 | 0.050 |
Why?
|
| Middle Aged | 6 | 2015 | 16542 | 0.050 |
Why?
|
| Cyclin I | 1 | 2023 | 1 | 0.050 |
Why?
|
| Secretory Vesicles | 1 | 2023 | 22 | 0.050 |
Why?
|
| Glutamate Decarboxylase | 1 | 2002 | 22 | 0.050 |
Why?
|
| CD3 Complex | 2 | 2018 | 64 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2002 | 130 | 0.050 |
Why?
|
| Immunoconjugates | 1 | 2002 | 84 | 0.050 |
Why?
|
| Bursa of Fabricius | 1 | 2001 | 1 | 0.050 |
Why?
|
| Cell Transformation, Viral | 1 | 2001 | 16 | 0.050 |
Why?
|
| Cellular Microenvironment | 1 | 2021 | 20 | 0.050 |
Why?
|
| Antibodies, Heterophile | 1 | 2001 | 2 | 0.050 |
Why?
|
| Antiviral Agents | 1 | 2024 | 317 | 0.050 |
Why?
|
| Lymphoma | 1 | 2001 | 100 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2011 | 93 | 0.040 |
Why?
|
| Twins | 1 | 2000 | 52 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2002 | 2892 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2020 | 59 | 0.040 |
Why?
|
| DNA | 2 | 1999 | 802 | 0.040 |
Why?
|
| HIV-1 | 1 | 2005 | 710 | 0.040 |
Why?
|
| Conserved Sequence | 1 | 1999 | 170 | 0.040 |
Why?
|
| Base Sequence | 2 | 1999 | 1301 | 0.040 |
Why?
|
| Coculture Techniques | 2 | 2009 | 94 | 0.040 |
Why?
|
| Transglutaminases | 1 | 2018 | 13 | 0.040 |
Why?
|
| Dexamethasone | 1 | 1999 | 197 | 0.040 |
Why?
|
| Insecta | 1 | 2018 | 37 | 0.040 |
Why?
|
| Glucagon | 1 | 2018 | 34 | 0.040 |
Why?
|
| HIV Infections | 1 | 2005 | 927 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 2018 | 80 | 0.040 |
Why?
|
| Protein-Arginine Deiminases | 1 | 2018 | 85 | 0.040 |
Why?
|
| Interleukin-6 | 2 | 2009 | 309 | 0.040 |
Why?
|
| Enzyme Activation | 1 | 2018 | 357 | 0.040 |
Why?
|
| Goats | 1 | 2017 | 9 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 34 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2018 | 296 | 0.030 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2016 | 15 | 0.030 |
Why?
|
| Thiazoles | 1 | 2016 | 46 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 329 | 0.030 |
Why?
|
| Indoles | 1 | 2016 | 102 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2016 | 125 | 0.030 |
Why?
|
| Microscopy, Fluorescence | 1 | 2017 | 399 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2015 | 37 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 157 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 2074 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2000 | 1542 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2009 | 944 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 1994 | 100 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2017 | 639 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 1145 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 713 | 0.020 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 1 | 2011 | 10 | 0.020 |
Why?
|
| Inflammation | 1 | 2018 | 1111 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2011 | 129 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 853 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2017 | 2480 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2011 | 250 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2011 | 171 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2016 | 495 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 1994 | 1224 | 0.020 |
Why?
|
| Quantum Theory | 1 | 2010 | 8 | 0.020 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2010 | 19 | 0.020 |
Why?
|
| Histocompatibility Testing | 1 | 2010 | 31 | 0.020 |
Why?
|
| Hyperinsulinism | 1 | 2010 | 24 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 2466 | 0.020 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2009 | 15 | 0.020 |
Why?
|
| Galectins | 1 | 2009 | 7 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 168 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 305 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2010 | 292 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2009 | 98 | 0.020 |
Why?
|
| Biological Transport, Active | 1 | 2008 | 38 | 0.020 |
Why?
|
| Aged | 2 | 2017 | 13596 | 0.020 |
Why?
|
| Autopsy | 1 | 2008 | 46 | 0.020 |
Why?
|
| Phagosomes | 1 | 2008 | 44 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 288 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2008 | 15 | 0.020 |
Why?
|
| Portal Vein | 1 | 2008 | 38 | 0.020 |
Why?
|
| Atrophy | 1 | 2008 | 68 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2008 | 21 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 115 | 0.020 |
Why?
|
| HLA-D Antigens | 1 | 2008 | 19 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2008 | 189 | 0.020 |
Why?
|
| Interleukin-1beta | 1 | 2009 | 262 | 0.020 |
Why?
|
| Meningioma | 1 | 2008 | 58 | 0.020 |
Why?
|
| Pregnancy | 1 | 2015 | 2361 | 0.020 |
Why?
|
| Immunologic Memory | 1 | 2009 | 282 | 0.020 |
Why?
|
| Protease Inhibitors | 1 | 2008 | 103 | 0.020 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2006 | 8 | 0.020 |
Why?
|
| Cell Division | 2 | 2002 | 442 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2008 | 252 | 0.020 |
Why?
|
| CD8 Antigens | 1 | 2006 | 54 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 129 | 0.020 |
Why?
|
| Mustard Compounds | 1 | 1986 | 1 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1571 | 0.020 |
Why?
|
| Mustard Gas | 1 | 1986 | 3 | 0.020 |
Why?
|
| Deoxyguanosine | 1 | 1986 | 20 | 0.020 |
Why?
|
| Kinetics | 1 | 2008 | 737 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2006 | 78 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 211 | 0.020 |
Why?
|
| Methyltransferases | 1 | 1986 | 50 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 2006 | 192 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2008 | 492 | 0.020 |
Why?
|
| Receptors, LDL | 1 | 2005 | 33 | 0.020 |
Why?
|
| Ionophores | 1 | 2005 | 10 | 0.020 |
Why?
|
| Ionomycin | 1 | 2005 | 15 | 0.020 |
Why?
|
| Arthritis, Experimental | 1 | 2005 | 29 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2005 | 65 | 0.020 |
Why?
|
| Carcinogens | 1 | 2005 | 37 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 525 | 0.020 |
Why?
|
| Membrane Fusion | 1 | 2005 | 77 | 0.010 |
Why?
|
| DNA Repair | 1 | 1986 | 236 | 0.010 |
Why?
|
| Endosomes | 1 | 2005 | 170 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 2005 | 203 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2009 | 766 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2003 | 122 | 0.010 |
Why?
|
| Salmonella typhimurium | 1 | 2003 | 80 | 0.010 |
Why?
|
| B7-2 Antigen | 1 | 2002 | 32 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2008 | 579 | 0.010 |
Why?
|
| Abatacept | 1 | 2002 | 63 | 0.010 |
Why?
|
| CD28 Antigens | 1 | 2002 | 59 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 2002 | 68 | 0.010 |
Why?
|
| Interleukin-13 | 1 | 2002 | 35 | 0.010 |
Why?
|
| B7-1 Antigen | 1 | 2002 | 73 | 0.010 |
Why?
|
| Antigens, Differentiation | 1 | 2002 | 141 | 0.010 |
Why?
|
| Transfection | 1 | 2003 | 673 | 0.010 |
Why?
|
| Avian Leukosis Virus | 1 | 2001 | 3 | 0.010 |
Why?
|
| Apoptosis | 2 | 1999 | 1042 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 1908 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2001 | 50 | 0.010 |
Why?
|
| Cell Line | 1 | 2005 | 2008 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2002 | 343 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2003 | 632 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1999 | 49 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 448 | 0.010 |
Why?
|
| Antibodies, Blocking | 1 | 1999 | 40 | 0.010 |
Why?
|
| Autocrine Communication | 1 | 1999 | 31 | 0.010 |
Why?
|
| fas Receptor | 1 | 1999 | 54 | 0.010 |
Why?
|
| Cell Movement | 1 | 2001 | 426 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1999 | 164 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 667 | 0.010 |
Why?
|
| Triplets | 1 | 1998 | 2 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 1999 | 227 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 1998 | 71 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 1999 | 304 | 0.010 |
Why?
|
| Twins, Monozygotic | 1 | 1998 | 70 | 0.010 |
Why?
|
| Diseases in Twins | 1 | 1998 | 55 | 0.010 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 1994 | 13 | 0.010 |
Why?
|
| Retinoblastoma Protein | 1 | 1994 | 37 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2001 | 2507 | 0.010 |
Why?
|
| Disease Progression | 1 | 1998 | 1053 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1994 | 453 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 1994 | 161 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1994 | 133 | 0.010 |
Why?
|
| Cell Cycle | 1 | 1994 | 382 | 0.010 |
Why?
|
| Phosphorylation | 1 | 1994 | 860 | 0.010 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 1986 | 4 | 0.000 |
Why?
|
| Alkylation | 1 | 1986 | 11 | 0.000 |
Why?
|
| Guanine | 1 | 1986 | 22 | 0.000 |
Why?
|
| Adenine | 1 | 1986 | 46 | 0.000 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1986 | 195 | 0.000 |
Why?
|
| Cattle | 1 | 1986 | 305 | 0.000 |
Why?
|